Immunosuppressive medications may help to reduce inflammation in the heart and the overall burden of primary heart involvement that is associated with systemic sclerosis (SSc), a retrospective study suggests. Larger studies are needed to confirm these findings, its researchers stated. The study, “Immunosuppressive therapy to treat newly diagnosed…
News
The CCL2 gene, which codes for a signaling protein of the same name, is “a common characteristic gene” of both systemic sclerosis (SSc) and idiopathic pulmonary fibrosis (IPF), a serious complication of SSc that causes the lungs to become inflamed and scarred, according to…
Autotaxin, a protein involved in wound healing and scarring, or fibrosis, was found at higher levels in women with systemic sclerosis-associated interstitial lung disease (SSc-ILD) than in men with the condition, per a new U.S. study. According to the researchers, “this study is the first to report sex-specific ……
Scleroderma (SSc) patients who’ve had a scleroderma renal crisis, a life-threatening complication of SSc, have higher levels of placental growth factor (PIGF), protein that stimulates blood vessel growth, in their blood than those who haven’t had one, a study in France shows. Among French patients who’d had a…
Organ involvement and outcomes among people with systemic sclerosis (SSc) are strongly associated with seven specific self-reactive antibodies, a French study has found. Among their findings, researchers identified antibodies that targets RNA polymerase III as strongly associated with scleroderma renal crisis, a rare and severe manifestation of SSc marked…
Zura Bio has launched a Phase 2 trial to evaluate the safety and efficacy of tibulizumab, its experimental dual pathway antibody to treat systemic sclerosis (SSc). The TibuSURE trial is expected to enroll as many as 80 adults with early diffuse cutaneous SSc. They will receive tibulizumab…
Reduction in skin thickness may indicate better lung health and survival outcomes in people with diffuse cutaneous systemic sclerosis (dcSSc), according to an analysis of patients from the European Scleroderma Trials and Research (EUSTAR) registry. “Skin regressive patients have a lower probability of lung progression, better survival,” the investigators…
Interstitial lung disease (ILD), a condition in which scarring damages lung tissue and makes breathing difficult, may appear several years after other symptoms of scleroderma (SSc) start, a study reported. Late-onset ILD in SSc was similar lung in severity and progression to the early-onset presentation. “Surveillance for incident…
Fatigue levels in people with scleroderma, also known as systemic sclerosis or SSc, are tied to several social, demographic, lifestyle, and disease-related factors, according to a study by a multinational team of researchers. Smoking, higher body mass index (BMI) —…
Soquelitinib, Corvus Pharmaceuticals’ immune-modulating investigational oral treatment for autoimmune diseases and certain cancers, reduced the signs and symptoms of lung disease caused by systemic sclerosis (SSc), according to new preclinical data. Designed to selectively block ITK, an enzyme predominantly found in immune T-cells, soquelitinib suppresses Th2 cells —…
Recent Posts
- More SSc-ILD patients receive early treatment, new study finds
- CD13 levels elevated in scleroderma, but biomarker value unclear
- New lab findings support development of stem cell treatments for SSc-ILD
- Type of immune cell may be key driver of scleroderma scarring: Study
- Abnormal fatty acid metabolism may play role in scleroderma: Analysis
- Cosmetic laser therapy could be repurposed for localized scleroderma
- Antibody levels may help reflect quality of life in people with scleroderma
- Certain antibodies tied to poorer outcomes in systemic sclerosis
- Dexamethasone reduces inflammation, scarring in SSc mouse model: Study
- Survival improves for SSc-PAH patients on combination therapy